Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhanglin Lin

Showing results (81-90 of 105) with videos related to

Pageof 11
Sort By:
International Journal of Biological Macromolecules|May 2, 2024
Enhancing the stability of a novel D-allulose 3-epimerase from Ruminococcus sp. CAG55 by interface interaction engineering and terminally attached a self-assembling peptideJing Wang, Chenlin Lu, Xuemei Shen, et al.
Journal of Medical Economics|October 10, 2019
Value of clinical trial narrative data to estimate the costs of adverse event management: a feasibility studyDeirdre Mladsi, Lisa M Hess, Christine L Barnett, et al.
Future Oncology (London, England)|February 23, 2019
Sequential therapy with ramucirumab and/or checkpoint inhibitors for non-small-cell lung cancer in routine practiceCliff Molife, Lisa M Hess, Zhanglin Lin Cui, et al.
Journal of Gastrointestinal Cancer|December 16, 2016
Patient Experience After Receiving a Diagnosis of Gastric Cancer in the USALisa M Hess, Zhanglin Lin Cui, Yixun Wu, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|February 5, 2018
Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practicesA Scott Paulson, Lisa M Hess, Astra M Liepa, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 23, 2020
Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL studyEdward B Garon, Katherine B Winfree, Cliff Molife, et al.
ACS Synthetic Biology|June 30, 2022
Mitigating Host Burden of Genetic Circuits by Engineering Autonegatively Regulated Parts and Improving Functional PredictionYing Guan, Xinmao Chen, Bin Shao, et al.
Applied Microbiology and Biotechnology|May 29, 2016
Semi-rational engineering of cytochrome CYP153A from Marinobacter aquaeolei for improved ω-hydroxylation activity towards oleic acidYan Duan, Lina Ba, Jianwei Gao, et al.
Future Oncology (London, England)|March 31, 2022
Generalizability of ORIENT-11 trial results to a US standard-of-care cohort with advanced non-small-cell lung cancerMisako Nagasaka, Cliff Molife, Zhanglin Lin Cui, et al.
Journal of Gastrointestinal Oncology|July 15, 2022
Treatment heterogeneity and overall survival in patients with advanced/metastatic gastric or gastroesophageal junction adenocarcinoma in the United StatesJessica A Davis, Zhanglin Lin Cui, Madiha Ghias, et al.
Pageof 11

Showing results (81-90 of 105) with videos related to

Sort By:
Pageof 11
International Journal of Biological Macromolecules|May 2, 2024
Enhancing the stability of a novel D-allulose 3-epimerase from Ruminococcus sp. CAG55 by interface interaction engineering and terminally attached a self-assembling peptideJing Wang, Chenlin Lu, Xuemei Shen, et al.
Journal of Medical Economics|October 10, 2019
Value of clinical trial narrative data to estimate the costs of adverse event management: a feasibility studyDeirdre Mladsi, Lisa M Hess, Christine L Barnett, et al.
Future Oncology (London, England)|February 23, 2019
Sequential therapy with ramucirumab and/or checkpoint inhibitors for non-small-cell lung cancer in routine practiceCliff Molife, Lisa M Hess, Zhanglin Lin Cui, et al.
Journal of Gastrointestinal Cancer|December 16, 2016
Patient Experience After Receiving a Diagnosis of Gastric Cancer in the USALisa M Hess, Zhanglin Lin Cui, Yixun Wu, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|February 5, 2018
Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practicesA Scott Paulson, Lisa M Hess, Astra M Liepa, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 23, 2020
Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL studyEdward B Garon, Katherine B Winfree, Cliff Molife, et al.
ACS Synthetic Biology|June 30, 2022
Mitigating Host Burden of Genetic Circuits by Engineering Autonegatively Regulated Parts and Improving Functional PredictionYing Guan, Xinmao Chen, Bin Shao, et al.
Applied Microbiology and Biotechnology|May 29, 2016
Semi-rational engineering of cytochrome CYP153A from Marinobacter aquaeolei for improved ω-hydroxylation activity towards oleic acidYan Duan, Lina Ba, Jianwei Gao, et al.
Future Oncology (London, England)|March 31, 2022
Generalizability of ORIENT-11 trial results to a US standard-of-care cohort with advanced non-small-cell lung cancerMisako Nagasaka, Cliff Molife, Zhanglin Lin Cui, et al.
Journal of Gastrointestinal Oncology|July 15, 2022
Treatment heterogeneity and overall survival in patients with advanced/metastatic gastric or gastroesophageal junction adenocarcinoma in the United StatesJessica A Davis, Zhanglin Lin Cui, Madiha Ghias, et al.
Pageof 11